Partner Investment Management L.P. lessened its stake in shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 18.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,033 shares of the company’s stock after selling 7,211 shares during the quarter. Partner Investment Management L.P. owned about 0.08% of Pacira Pharmaceuticals worth $1,525,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. US Bancorp DE boosted its holdings in shares of Pacira Pharmaceuticals by 40.7% during the second quarter. US Bancorp DE now owns 6,038 shares of the company’s stock worth $194,000 after purchasing an additional 1,746 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in shares of Pacira Pharmaceuticals by 1,925.8% during the second quarter. Cubist Systematic Strategies LLC now owns 6,665 shares of the company’s stock worth $214,000 after purchasing an additional 6,336 shares during the last quarter. Xact Kapitalforvaltning AB acquired a new stake in shares of Pacira Pharmaceuticals during the second quarter worth $219,000. Bouchey Financial Group Ltd acquired a new stake in shares of Pacira Pharmaceuticals during the third quarter worth $221,000. Finally, Boston Private Wealth LLC acquired a new stake in shares of Pacira Pharmaceuticals during the third quarter worth $246,000. Hedge funds and other institutional investors own 97.84% of the company’s stock.

NASDAQ:PCRX opened at $48.32 on Wednesday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 7.83 and a current ratio of 8.66. Pacira Pharmaceuticals Inc has a 12 month low of $26.95 and a 12 month high of $55.00. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of -83.31, a P/E/G ratio of 83.11 and a beta of 1.65.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Thursday, November 1st. The company reported $0.31 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.40. Pacira Pharmaceuticals had a positive return on equity of 2.74% and a negative net margin of 1.30%. The company had revenue of $83.45 million for the quarter, compared to analyst estimates of $79.87 million. During the same period last year, the company posted $0.11 earnings per share. The firm’s revenue was up 23.9% compared to the same quarter last year. Equities research analysts anticipate that Pacira Pharmaceuticals Inc will post 0.02 EPS for the current fiscal year.

In related news, Director Gary W. Pace acquired 4,500 shares of the business’s stock in a transaction on Monday, November 19th. The shares were bought at an average cost of $46.18 per share, with a total value of $207,810.00. Following the completion of the transaction, the director now directly owns 32,819 shares of the company’s stock, valued at approximately $1,515,581.42. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Lauren Bullaro Riker sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $54.35, for a total value of $54,350.00. Following the completion of the transaction, the vice president now directly owns 11,474 shares in the company, valued at $623,611.90. The disclosure for this sale can be found here. Insiders sold 151,221 shares of company stock worth $7,403,146 over the last three months. 5.90% of the stock is currently owned by corporate insiders.

Several equities research analysts have recently issued reports on PCRX shares. Canaccord Genuity set a $45.00 price objective on Pacira Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, September 4th. BMO Capital Markets raised their price objective on Pacira Pharmaceuticals from $40.00 to $47.00 and gave the stock a “market perform” rating in a report on Friday, November 2nd. Wedbush set a $90.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, November 5th. ValuEngine upgraded Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, October 18th. Finally, HC Wainwright increased their target price on Pacira Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a research report on Friday, November 2nd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the stock. Pacira Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $53.76.

TRADEMARK VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/partner-investment-management-l-p-has-1-53-million-holdings-in-pacira-pharmaceuticals-inc-pcrx/2662628.html.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

See Also: Float

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.